医学
毛细血管扩张
病理
疾病
突变
皮肤病科
免疫学
活检
免疫系统
梅德林
作者
Deku Liang,Yonghong Lin,Li He
摘要
To the Editor: In their article, Al-Samkari et al. (Nov. 27 issue) 1 indicate that hereditary hemorrhagic telangiectasia (HHT) is caused by mutations in the activin receptor–like kinase 1 (ALK1) signaling pathway and that pathogenic variants in ALK1 signaling lead to excessive activation of the serine–threonine kinase AKT downstream, thereby driving the formation of telangiectasia and arteriovenous malformation. Engasertib works by selectively inhibiting AKT1 and AKT2. However, to our knowledge, mutations in the ALK1 signaling pathway result in only one type of HHT. HHT can be caused by DNA variants in ENG (encoding endoglin), ACVRL1 (encoding ALK1), GDF2 (encoding growth differentiation . . .
科研通智能强力驱动
Strongly Powered by AbleSci AI